Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology ( ASCO ) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the ...
| Ticker |
Sentiment |
Impact |
|
BMY
|
Neutral
|
1 %
|
|
PPBT
|
Neutral
|
11 %
|
